Merck, Inc.
🇵🇭Philippines
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Completed
- Conditions
- GliomaAstrocytoma
- Interventions
- Drug: Temozolomide (for newly diagnosed malignant glioma)Drug: Temozolomide (for relapsed malignant glioma)Radiation: Radiotherapy (for patients with newly diagnosed malignant glioma)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1804
- Registration Number
- NCT00705198
An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)
Withdrawn
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00704756
Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)
Terminated
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 267
- Registration Number
- NCT00705107
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00704951
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Completed
- Conditions
- Hepatitis C VirusHepatitis C, Chronic
- Interventions
- Biological: Pegylated InterferonDrug: Ribavirin
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 250
- Registration Number
- NCT00705224
Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 285
- Registration Number
- NCT00704405
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)
Phase 2
Completed
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Drug: MK0777Drug: Placebo (unspecified)
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00703833
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Phase 2
Completed
- Conditions
- Hepatitis C
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00704184
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00704132
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00704054
© Copyright 2025. All Rights Reserved by MedPath